File Download
Supplementary

postgraduate thesis: Development of peptide-based inhibitors of YEATS2 YEATS as a novel strategy against non-small cell lung cancer

TitleDevelopment of peptide-based inhibitors of YEATS2 YEATS as a novel strategy against non-small cell lung cancer
Authors
Issue Date2023
PublisherThe University of Hong Kong (Pokfulam, Hong Kong)
Citation
Liu, S. [刘莎]. (2023). Development of peptide-based inhibitors of YEATS2 YEATS as a novel strategy against non-small cell lung cancer. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR.
AbstractEpigenetic proteins that regulate the writing, erasing, and reading of histone posttranslational modifications (PTMs) are emerging drug targets, given their essential roles in normal physiology and disease pathogenesis. YEATS domain represents a new class reader protein that recognizes histone acyl modifications such as acetylation, crotonylation, and benzoylation. The human YEATS domain-containing proteins (i.e., AF9, ENL, GAS41, and YEATS2) are involved in various molecular functions, such as transcription elongation, histone variant deposition, and chromatin remodeling. Dysregulation of the YEATS domain is often implicated in different types of cancers, including acute myeloid leukemia (AML) and non-small cell lung cancer (NSCLC). Considering their therapeutic potential, chemical inhibitors for ENL, AF9, and GAS41 have been developed. However, to date, no inhibitors have been developed targeting YEATS2 despite its crucial role in the ADA Two A-Containing (ATAC) histone acetyltransferase complex for transcription regulation and tumorigenesis of NSCLC. In Chapter 2, I developed first-in-class inhibitors targeting the YEATS domain of human YEATS2. Guided by the structural analysis of the YEATS2 YEATS-H3K27bz complex, I synthesized peptide-derived inhibitors by replacing the benzoyl group with expanded systems or changing the surrounding residues against the surface contacts outside the Kbz-binding pocket. The subsequent structure-activity relationship study has led to the discovery of a potent inhibitor with 89 nM dissociation constant (Kd) toward YEATS2 in vitro. The further optimization of drug-like properties resulted in a potent, selective, and cellularly active inhibitor named LS-170, which efficiently inhibited the proliferation and colony formation of NSCLC cells. In Chapter 3, the mechanistic and pharmacological role of LS-170 targeting the YEATS2 YEATS domain in NSCLC was investigated. Photo-cross-linking-based pulldown and fluorescence recovery after photobleaching (FRAP) assays showed LS-170 could selectively engage with endogenous YEATS2 but not other YEATS-containing proteins in cells. Armed with this powerful chemical tool, we detailed the biological response of NSCLC cells to pharmacological YEATS2 disruption. Notably, we discovered that YEATS2 YEATS inhibition is sufficient to selectively suppress YEATS2 target genes, including MCMs, CDC6, CCNE2, TK1, and GINS, a subset of cell division-related genes that are highly amplified in NSCLC. In a xenograft mouse model, LS-170 significantly suppressed the NSCLC tumor growth without apparent toxicity. Collectively, our study provided the first thoroughly characterized inhibitors for the YEATS2 YEATS domain and established the YEATS2 YEATS domain inhibition as a feasible strategy to impair the pathogenic function of YEATS2 in NSCLC.
DegreeDoctor of Philosophy
SubjectLungs - Cancer - Genetic aspects
Post-translational modification
Dept/ProgramChemistry
Persistent Identifierhttp://hdl.handle.net/10722/353370

 

DC FieldValueLanguage
dc.contributor.authorLiu, Sha-
dc.contributor.author刘莎-
dc.date.accessioned2025-01-17T09:46:07Z-
dc.date.available2025-01-17T09:46:07Z-
dc.date.issued2023-
dc.identifier.citationLiu, S. [刘莎]. (2023). Development of peptide-based inhibitors of YEATS2 YEATS as a novel strategy against non-small cell lung cancer. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR.-
dc.identifier.urihttp://hdl.handle.net/10722/353370-
dc.description.abstractEpigenetic proteins that regulate the writing, erasing, and reading of histone posttranslational modifications (PTMs) are emerging drug targets, given their essential roles in normal physiology and disease pathogenesis. YEATS domain represents a new class reader protein that recognizes histone acyl modifications such as acetylation, crotonylation, and benzoylation. The human YEATS domain-containing proteins (i.e., AF9, ENL, GAS41, and YEATS2) are involved in various molecular functions, such as transcription elongation, histone variant deposition, and chromatin remodeling. Dysregulation of the YEATS domain is often implicated in different types of cancers, including acute myeloid leukemia (AML) and non-small cell lung cancer (NSCLC). Considering their therapeutic potential, chemical inhibitors for ENL, AF9, and GAS41 have been developed. However, to date, no inhibitors have been developed targeting YEATS2 despite its crucial role in the ADA Two A-Containing (ATAC) histone acetyltransferase complex for transcription regulation and tumorigenesis of NSCLC. In Chapter 2, I developed first-in-class inhibitors targeting the YEATS domain of human YEATS2. Guided by the structural analysis of the YEATS2 YEATS-H3K27bz complex, I synthesized peptide-derived inhibitors by replacing the benzoyl group with expanded systems or changing the surrounding residues against the surface contacts outside the Kbz-binding pocket. The subsequent structure-activity relationship study has led to the discovery of a potent inhibitor with 89 nM dissociation constant (Kd) toward YEATS2 in vitro. The further optimization of drug-like properties resulted in a potent, selective, and cellularly active inhibitor named LS-170, which efficiently inhibited the proliferation and colony formation of NSCLC cells. In Chapter 3, the mechanistic and pharmacological role of LS-170 targeting the YEATS2 YEATS domain in NSCLC was investigated. Photo-cross-linking-based pulldown and fluorescence recovery after photobleaching (FRAP) assays showed LS-170 could selectively engage with endogenous YEATS2 but not other YEATS-containing proteins in cells. Armed with this powerful chemical tool, we detailed the biological response of NSCLC cells to pharmacological YEATS2 disruption. Notably, we discovered that YEATS2 YEATS inhibition is sufficient to selectively suppress YEATS2 target genes, including MCMs, CDC6, CCNE2, TK1, and GINS, a subset of cell division-related genes that are highly amplified in NSCLC. In a xenograft mouse model, LS-170 significantly suppressed the NSCLC tumor growth without apparent toxicity. Collectively, our study provided the first thoroughly characterized inhibitors for the YEATS2 YEATS domain and established the YEATS2 YEATS domain inhibition as a feasible strategy to impair the pathogenic function of YEATS2 in NSCLC. -
dc.languageeng-
dc.publisherThe University of Hong Kong (Pokfulam, Hong Kong)-
dc.relation.ispartofHKU Theses Online (HKUTO)-
dc.rightsThe author retains all proprietary rights, (such as patent rights) and the right to use in future works.-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subject.lcshLungs - Cancer - Genetic aspects-
dc.subject.lcshPost-translational modification-
dc.titleDevelopment of peptide-based inhibitors of YEATS2 YEATS as a novel strategy against non-small cell lung cancer-
dc.typePG_Thesis-
dc.description.thesisnameDoctor of Philosophy-
dc.description.thesislevelDoctoral-
dc.description.thesisdisciplineChemistry-
dc.description.naturepublished_or_final_version-
dc.date.hkucongregation2024-
dc.identifier.mmsid991044857814903414-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats